title: Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition.
abstract: The monoclonal antibody MA-33B8, directed against the serpin plasminogen activator inhibitor-1 (PAI-1), has unique functional properties as it induces acceleration of the active-to-latent transition (Verhamme I et al. J Biol Chem 274: 17511-7, 1999), resulting in PAI-1 activity neutralization. In this study, we have identified Lys(88), Asp(89), Lys(176) and His(229) as the major residues of the conformational epitope. Lysine(88) and aspartic acid(89), contributing the most, are located on the loop between alpha-helix D and beta-strand 2A. Strikingly, these residues undergo dramatic conformational changes during latency conversion. The three dimensional localization of this epitope and its differential exposure in active and latent forms of PAI-1 provide a molecular explanation for the underlying mechanism of MA-33B8. Rearrangements of hydrogen bonds in this region upon latency transition, strongly suggest that binding of MA-33B8 may result in the generation of energy required in the rate-limiting step of latency transition. Thus, this novel epitope reveals a new interaction site in PAI-1 as a putative molecular target to modulate PAI-1 activity.
authors.affiliation: Laboratory for Pharmaceutical Biology and Phytocpharmacology, Faculty of Pharmaceutical Sciences, K U Leuven, Belgium.
authors.forename: Dominik
authors.initials: D
authors.lastname: Naessens
authors.forename: Ann
authors.initials: A
authors.lastname: Gils
authors.forename: Griet
authors.initials: G
authors.lastname: Compernolle
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Declerck
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D000915:Antibody Affinity; D000937:Antigen-Antibody Reactions; D015195:Drug Design; D004734:Energy Metabolism; D000939:Epitopes / Q000737:chemistry / Q000276:immunology*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans; D006860:Hydrogen Bonding; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D017395:Plasminogen Activator Inhibitor 1 / Q000737:chemistry / Q000276:immunology*; D011487:Protein Conformation / Q000187:drug effects; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D000939:Epitopes; D005343:Fibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1